PRA Health, Alliance for Multispecialty Research team up on vaccines
"This is an ideal collaboration," Frank Hijek, PRA's senior vice president for strategic drug development, said. "It combines the expertise of PRA, one of the world's leading contract research organizations, and AMR, one of the most effective clinical research site networks in the industry. Together, we can help sponsors get vaccines to the people who need them."
AMR has a 98 percent subject-retention rate, which both companies believe will help sponsors meet enrollment timelines. AMR’s primary goal is to provide clinical study services, including vaccines and several bioterrorism-related, government-sponsored programs.
PRA has conducted medical studies at more than 3,000 facilities around the world, with almost 213,000 patient participants. As a result, PRA has provided support for 10 approved vaccines in the past five years while supporting four of the five top vaccine manufacturers.
"Our partnership with PRA allows us to provide a simple approach to effective vaccine studies," AMR CEO Brenda Atchison said. "Our respective expertise will allow us to make significant strides in implementing efficient solutions to smarter vaccine development."
The majority of vaccines are pediatric, but the adult vaccine market is expected to double by 2020, especially in the area of infectious diseases that affect people around the world. The PRA and AMR collaboration is expected to identify patient populations needed for vaccine studies and get new vaccines to market quicker than in the past.